broadspectrum
antiparasit
agent
ivermectin
recent
found
inhibit
vitro
propos
candid
drug
repurpos
present
report
vitro
antivir
activ
endpoint
analyz
pharmacokinet
perspect
avail
pharmacokinet
data
clinic
relev
excess
dose
studi
indic
inhibitori
concentr
like
attain
human
pandem
fuell
much
research
effort
toward
repurpos
exist
drug
possibl
antivir
agent
wherebi
therapeut
strategi
larg
base
preexist
data
preced
coronavir
outbreak
tor
mer
drug
regulatori
agenc
health
author
key
opinion
leader
polici
decis
maker
significantli
strain
dilemma
evidencebas
medicin
good
clinic
practic
versu
prompt
need
safe
effect
treatment
unfortun
wit
huge
public
polit
pressur
legitim
drugrepurpos
offlabel
use
worldwid
nonetheless
could
regard
accept
compromis
pend
emerg
current
situat
case
drug
welldefin
safeti
profil
least
clinic
evid
convers
treatment
protocol
base
observ
studi
anecdot
report
albeit
hope
promptli
emerg
data
random
studi
enabl
switch
treatment
back
avenu
evidencebas
medicin
except
alarm
phenomenon
howev
public
commun
drug
preliminari
vitro
activ
potenti
therapeut
eventu
caus
malign
reverber
social
media
exampl
otherwis
interest
studi
cali
et
al
recent
publish
antivir
research
paper
describ
vitro
antivir
activ
antiparasit
agent
ivermectin
model
verohslam
cell
infect
isol
author
perform
pilot
experi
use
continu
exposur
cell
ivermectin
found
timedepend
decreas
cell
associ
supernat
viral
rna
thereaft
antivir
activ
assess
follow
continu
exposur
serial
dilut
ivermectin
caus
concentrationdepend
antivir
effect
practic
total
erad
halfmaxim
inhibit
approxim
academ
virolog
pharmacolog
impact
newli
discov
antivir
effect
ivermectin
beyond
doubt
nevertheless
notion
possibl
clinic
translat
repurpos
gener
enorm
media
coverag
need
care
address
refer
pharmacokinet
ivermectin
paper
sought
analyz
dose
regimen
drug
avail
maxim
plasma
concentr
level
allow
detail
juxtaposit
inhibitori
effect
question
paradigm
plausibl
ivermectin
repurpos
literatur
survey
perform
order
analyz
publish
dose
regimen
collect
human
exposur
data
ivermectin
follow
clinic
relev
excess
dose
avail
pharmacokinet
data
ivermectin
patient
parasit
infect
healthi
volunt
pool
maxim
plasma
concentr
level
c
max
use
surrog
juxtaposit
vitro
inhibitori
find
publish
concentr
shown
antivir
activ
recalcul
ngml
allow
direct
comparison
pharmacokinet
data
ivermectin
valuabl
clinic
role
manag
differ
parasit
diseas
wherebi
describ
therapeut
regimen
could
summar
follow
yearli
treatment
onchocerciasi
singl
dose
strongyloidiasi
twice
yearli
altern
yearli
endem
area
lymphat
filariasi
conjunct
topic
drug
hyperkeratot
also
known
crust
norwegian
scabi
ivermectin
semisynthet
analogu
natur
product
avermectin
b
lipophil
macrolid
isol
streptomyc
avermitili
develop
crop
manag
insecticid
ivermectin
affect
plethora
ivertebr
speci
incl
parasit
nematod
arachnid
insect
mode
action
target
speci
potenti
gabamedi
neurotransmiss
bind
glutamateg
clchannel
found
invertebr
drug
induc
tonic
paralysi
musculatur
suscept
parasit
eventu
death
recommend
dose
ivermectin
readili
penetr
cn
mammal
gaba
function
neurotransmitt
convers
healthi
volunt
infect
patient
drug
usual
well
toler
therapeut
dose
rang
recent
metaanalysi
shown
even
larger
dose
sever
year
period
followup
could
well
toler
patient
parasit
infect
largest
dose
intens
regist
pharmacokinet
paramet
healthi
subject
mg
correspond
evid
form
analyz
pharmacokinet
data
clinic
appli
dosag
schedul
aforement
excess
mg
dose
yield
blood
level
nanogramml
ie
nanomolar
rang
tabl
concentr
order
magnitud
lower
compar
vitro
antivir
endpoint
describ
studi
cali
et
al
tabl
summar
vitro
inhibitori
concentr
recalcul
ngml
base
molecular
weight
allow
direct
juxtaposit
pharmacokinet
paramet
tabl
moreov
vitro
data
compar
c
max
valu
obtain
mg
mg
dose
correspond
dose
intens
respect
calcul
correspond
exposur
ratio
analyz
data
show
least
clinic
relev
dose
rang
ivermectin
publish
vitro
inhibitori
concentr
especi
level
caus
almost
total
disappear
viral
rna
virtual
achiev
heretofor
known
dose
regimen
human
concentr
time
higher
level
obtain
time
higher
vs
largest
c
max
found
literatur
survey
ngml
moreov
author
claim
achiev
viral
inhibit
singl
dose
inappropri
practic
infect
cell
continu
expos
concentr
virtual
unattain
even
excess
dose
drug
word
experiment
design
base
clinic
irrelev
drug
level
inhibitori
concentr
whose
target
clinic
trial
seem
doubt
best
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
tabl
comparison
vitro
inhibitori
concentr
ivermectin
exemplar
publish
c
max
valu
drug
vitro
endpoint
inhibitori
concentr
repurpos
antimalari
drug
hydroxychloroquin
chloroquin
includ
numer
treatment
protocol
also
micromolar
inhibitori
concentr
nanomolar
c
max
valu
nevertheless
agent
enorm
appar
volum
distribut
presum
disproport
larger
tissu
level
rel
plasma
concentr
make
translat
vitro
data
plausibl
promis
agent
test
clinic
trial
appli
compassion
use
remdesivir
broadspectrum
antivir
drug
origin
develop
ebola
show
potent
inhibitori
effect
ic
ngml
concentr
readili
attain
drug
given
venou
infus
typic
dose
schedul
remdesiviriniti
infus
mg
follow
mgdaili
total
day
yield
maxim
plasma
concentr
ngml
first
day
day
case
ivermectin
howev
potenti
repurpos
plausibl
present
like
antivir
concentr
would
attain
massiv
overdos
therapeut
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
applic
ivermectin
usual
associ
signific
toxic
wherebi
major
document
advers
effect
nausea
rash
dizzi
itch
eosinophilia
abdomin
pain
fever
tachycardia
could
gener
attribut
gross
lethal
invad
microfilaria
give
rise
mazzottilik
reaction
nevertheless
larg
dose
drug
could
penetr
bloodbrain
barrier
could
affect
gabaerg
transmiss
caus
cn
depress
potenti
effect
benzodiazepin
human
exposur
dose
multifold
higher
therapeut
expect
give
rise
side
effect
similar
document
preclin
mammalian
test
human
overdos
associ
vomit
tachycardia
ecg
abnorm
signific
blood
pressur
fluctuat
cn
effect
drowsi
ataxia
visual
disturb
mydriasi
accident
selfinject
veterinari
medicin
product
produc
sign
clinic
toxic
albeit
drug
appli
therapeut
relev
dose
approxim
emphas
gener
public
commun
drug
potenti
therapeut
base
sole
vitro
data
neither
scientif
ethic
appropri
ivermectin
previous
shown
exert
antivir
activ
vitro
dengu
fever
viru
denv
influenza
viru
west
nile
viru
venezuelan
equin
enceph
viru
herald
possibl
antivir
drug
far
clinic
translat
data
noteworthi
clinic
trial
treatment
dengu
fever
thailand
fail
show
clinic
benefit
light
aforement
pharmacokinet
consider
surpris
given
publish
inhibitori
concentr
rang
world
alreadi
seen
epidem
selfmed
drug
shortag
even
overdos
chloroquin
hydroxychloroquin
unfortun
cali
et
al
studi
prompt
enorm
public
interest
potenti
evok
similar
tragic
sequel
especi
mind
mani
countri
drug
avail
solut
inject
veterinari
use
whose
potenti
seriou
toxicolog
outcom
human
unanim
bulgaria
particular
studi
prompt
nation
veterinarian
union
share
concern
hysteria
studi
evok
firmli
discourag
selfmed
ivermectin
countri
avail
use
anim
th
april
letter
stakehold
fda
similarli
share
concern
issu
explicitli
advis
attempt
selfmed
ivermectin
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
